PRESS RELEASE published on 02/29/2024 at 22:05, 6 months 18 days ago Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers Sonnet BioTherapeutics Holdings, Inc. announced the publication of clinical data on SON-1010, a tumor-targeted immunotherapeutic drug combining FHAB construct with IL-12 in Frontiers in Immunology, showing favorable safety and tolerability Clinical Data Sonnet BioTherapeutics SON-1010 Immunotherapeutic Drug FHAB Technology
PRESS RELEASE published on 02/14/2024 at 13:30, 7 months 4 days ago Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update Sonnet BioTherapeutics Holdings, Inc. successfully raised $4.55 million, published preclinical data on SON-1210, executed NJ NOLs agreement, Phase 1b SON-080 trial enrollment completed, financial results announced for quarter ended Dec 31, 2023 Financial Results Preclinical Data Public Offering Sonnet BioTherapeutics Holdings NJ NOLs
PRESS RELEASE published on 12/21/2023 at 14:00, 8 months 28 days ago Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
PRESS RELEASE published on 12/14/2023 at 22:15, 9 months 4 days ago Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
PRESS RELEASE published on 10/31/2023 at 12:30, 10 months 18 days ago Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
PRESS RELEASE published on 10/25/2023 at 13:30, 10 months 24 days ago Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
PRESS RELEASE published on 10/17/2023 at 14:00, 11 months 1 day ago Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
PRESS RELEASE published on 09/20/2023 at 13:30, 11 months 28 days ago Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
Published on 09/18/2024 at 23:10, 3 hours 57 minutes ago Ur-Energy Provides Operations, Construction and 2024 Guidance Updates
Published on 09/18/2024 at 23:00, 4 hours 7 minutes ago Garden State Gold & Coin Applauds Passage of Historic NJ Sales Tax Bill on Precious Metals
Published on 09/18/2024 at 21:15, 5 hours 52 minutes ago New to the Street Launches 24-Part Series with ARAX Holdings, Spotlighting Core Blockchain, CorePass, Lunaº Mesh, and Revolutionary Tech Solutions
Published on 09/18/2024 at 21:00, 6 hours 7 minutes ago Falcon Commences Drilling At Its Great Burnt Copper Project, NL
Published on 09/18/2024 at 16:30, 10 hours 37 minutes ago Manimal Tales Launches New Nursery Rhyme Based Detective Series: Your Child Solves Nursery Crimes in our Newest Personalized Book!
Published on 09/18/2024 at 19:11, 7 hours 56 minutes ago EQS-Adhoc: alstria office REIT-AG: squeeze-out demand regarding the shares of minority shareholders, amendment to investment agreement, loss of REIT-status at year-end 2024
Published on 09/18/2024 at 18:45, 8 hours 22 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/18/2024 at 18:31, 8 hours 35 minutes ago EQS-Adhoc: Vonovia SE: Initiation of the process to conclude a domination and profit and loss transfer agreement between Vonovia SE and Deutsche Wohnen SE
Published on 09/18/2024 at 18:13, 8 hours 54 minutes ago BILENDI: Creating discussion guides for market research is now possible with AI, thanks to BARI and Bilendi Discuss
Published on 09/18/2024 at 17:21, 9 hours 45 minutes ago EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
Published on 09/18/2024 at 18:45, 8 hours 21 minutes ago Augmentation de capital consécutive à l'attribution gratuite d'actions aux salariés du groupe EuropaCorp
Published on 09/18/2024 at 18:45, 8 hours 21 minutes ago Capital increase following the allocation of free shares to EuropaCorp employees
Published on 09/18/2024 at 17:40, 9 hours 27 minutes ago Groupe CRIT : Modalités de mise à disposition du Rapport Financier semestriel 2024.